Fig. 5From: Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survivalDifferential methylation associated with initial response does not provide information on response duration or progression. Heatmap showing the hierarchical clusterization of samples of response after more than 6 AZA cycles (n =9) and samples of progression (n =7) using the methylation status of CpG sites identified in Fig. 2Back to article page